直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Pharmaceutical company wins judgment based on filing date

Elan Pharmaceuticals

KV Pharmaceuticals (Paradissis)

We assisted our client Elan Pharmaceuticals in obtaining a judgment against Paradissis based on the benefit of the earlier filing date of Elan’s foreign priority application. The subject involved controlled-release pharmaceutical formulation for once-per-day administration.

Elan Pharmaceuticals v. KV Pharmaceuticals (Paradissis), Int. No. 104,617, BPAI, Sprizzo

Related Practices

Global IP Enforcement, Litigation, and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Experiences

Represented a pharmaceutical company before German Civil Patent Courts*

Startup sold to major drug company based on strength of patents

Agouron Pharmaceuticals, Inc.

Arbitration victory for major U.S. pharmaceutical company

Finnegan successfully represents U.S. pharmaceutical company in an arbitration

Assisted on a successful claim for an Arrow declaration on behalf of a major pharmaceutical company*

Global prosecution and portfolio management for major pharmaceutical company

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief*

Comprehensive patent transactions and strategic counseling for one of the largest pharmaceutical companies in the world

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company*

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP